References: |
Uprosertib, also known as GSK2141795 and GSK795, is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity.Akt inhibitor GSK2141795 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. For the detailed information of Uprosertib (GSK-2141795,GSK795), the solubility of Uprosertib (GSK-2141795,GSK795) in water, the solubility of Uprosertib (GSK-2141795,GSK795) in DMSO, the solubility of Uprosertib (GSK-2141795,GSK795) in PBS buffer, the animal experiment (test) of Uprosertib (GSK-2141795,GSK795), the cell expriment (test) of Uprosertib (GSK-2141795,GSK795), the in vivo, in vitro and clinical trial test of Uprosertib (GSK-2141795,GSK795), the EC50, IC50,and affinity,of Uprosertib (GSK-2141795,GSK795), Please contact DC Chemicals. |